BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24869799)

  • 1. Body mass index, diabetes, and triple-negative breast cancer prognosis.
    Tait S; Pacheco JM; Gao F; Bumb C; Ellis MJ; Ma CX
    Breast Cancer Res Treat; 2014 Jul; 146(1):189-97. PubMed ID: 24869799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body mass index and weight change in relation to triple-negative breast cancer survival.
    Bao PP; Cai H; Peng P; Gu K; Su Y; Shu XO; Zheng Y
    Cancer Causes Control; 2016 Feb; 27(2):229-36. PubMed ID: 26621544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does obesity have an effect on outcomes in triple-negative breast cancer?
    Mowad R; Chu QD; Li BD; Burton GV; Ampil FL; Kim RH
    J Surg Res; 2013 Sep; 184(1):253-9. PubMed ID: 23768767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Being Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection.
    Choi Y; Park SK; Ahn KJ; Cho H; Kim TH; Yoon HK; Lee YH
    J Korean Med Sci; 2016 Jun; 31(6):886-91. PubMed ID: 27247497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Body Mass Index in Triple Negative Breast Cancer.
    Cakar B; Muslu U; Erdogan AP; Ozisik M; Ozisik H; Tunakan Dalgic C; Durusoy R; Karaca B; Sezgin C; Karabulut B; Uslu R
    Oncol Res Treat; 2015; 38(10):518-22. PubMed ID: 26452262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
    Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
    Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Body mass index and cancer incidence:a prospective cohort study in northern China].
    Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
    Widschwendter P; Friedl TW; Schwentner L; DeGregorio N; Jaeger B; Schramm A; Bekes I; Deniz M; Lato K; Weissenbacher T; Kost B; Andergassen U; Jueckstock J; Neugebauer J; Trapp E; Fasching PA; Beckmann MW; Schneeweiss A; Schrader I; Rack B; Janni W; Scholz C
    Breast Cancer Res; 2015 Sep; 17(1):129. PubMed ID: 26385214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
    Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
    Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression in triple-negative breast cancer in relation to survival.
    Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
    Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
    Tung N; Gaughan E; Hacker MR; Lee LJ; Alexander B; Poles E; Schnitt SJ; Garber JE
    Breast Cancer Res Treat; 2014 Jul; 146(1):175-82. PubMed ID: 24839033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
    Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
    Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: An institutional analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK
    Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
    Steward L; Conant L; Gao F; Margenthaler JA
    Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of overweight and obesity in a breast clinic population: consideration for weight loss as a therapeutic intervention.
    Kim A; Scharf K; Senthil M; Solomon N; Garberoglio C; Lum SS
    Surg Obes Relat Dis; 2014; 10(2):348-53. PubMed ID: 24094868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.
    Ladoire S; Dalban C; Roché H; Spielmann M; Fumoleau P; Levy C; Martin AL; Ecarnot F; Bonnetain F; Ghiringhelli F
    Eur J Cancer; 2014 Feb; 50(3):506-16. PubMed ID: 24315625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.